🇺🇸 FDA
Pipeline program

Baxdrostat, Baxdrostat, Baxdrostat Placebo

D6974C00001

Phase 3 small_molecule active

Quick answer

Baxdrostat, Baxdrostat, Baxdrostat Placebo for Primary Aldosteronism defined by excess aldosterone secretion is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca AB
Indication
Primary Aldosteronism defined by excess aldosterone secretion
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials